Security
Tonix Pharmaceuticals Holding Corp. Common Stock · TNXP
TNXPNASDAQCommon stockCurrentCIK 1430306Updated Nov 11, 2026
Name history
TAMANDARE EXPLORATIONS INC. · through Oct 17, 2011
TNXP price & chart
Loading TradingView…
NASDAQ:TNXP on TradingView ↗In the news
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026 ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Results of Operations and Financial Condition · Other Events
Items 2.02, 8.01
Other Events
Items 8.01
Other Events
Items 8.01, 9.01
Show 5 more recent filings
Other Events
Items 8.01, 9.01
4 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 5.02, 8.01
SCHEDULE 13G/A - filed by Sirenia Capital Management LP regarding Tonix Pharmaceuticals Holding Corp.
10-Q filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 252,440,000Source | 94,989,000Source | 254,088,000Source | 187,359,000Source | 70,307,000Source | 257,912,000Source | 192,870,000Source | 135,343,000Source | 277,171,000Source | 162,890,000Source | 154,457,000Source | 225,690,000Source |
| Property, Plant and Equipment, NetUSD | 42,574,000Source | 42,747,000Source | 44,760,000Source | 42,335,000Source | 43,247,000Source | 44,894,000Source | 41,766,000Source | 93,058,000Source | 44,456,000Source | 42,252,000Source | 94,028,000Source | 93,814,000Source |
| GoodwillUSD | — | — | — | — | — | — | — | 965,000Source | — | — | 965,000Source | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 120,000Source | 120,000Source | — | 120,000Source | 120,000Source | 120,000Source | 120,000Source | 9,505,000Source | 120,000Source | 120,000Source | 9,743,000Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 190,055,000Source | 28,233,000Source | 176,232,000Source | 125,331,000Source | 4,156,000Source | 185,470,000Source | 131,716,000Source | 7,049,000Source | 207,637,000Source | 98,776,000Source | 24,948,000Source | 120,229,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 3,481,000Source | 4,013,000Source | 11,805,000Source | 2,320,000Source | 3,339,000Source | 8,820,000Source | 3,312,000Source | — | 6,271,000Source | 3,683,000Source | — | — |
| Inventory, NetUSD | — | 7,931,000Source | — | — | 9,457,000Source | — | — | 12,351,000Source | — | 8,408,000Source | 13,639,000Source | — |
| Assets, CurrentUSD | 208,071,000Source | 50,543,000Source | 203,432,000Source | 143,535,000Source | 25,287,000Source | 207,168,000Source | 149,573,000Source | 30,098,000Source | 228,876,000Source | 119,002,000Source | 47,768,000Source | 130,777,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 8,806,000Source | 10,366,000Source | 10,717,000Source | 9,898,000Source | 8,335,000Source | 9,233,000Source | 6,409,000Source | 10,698,000Source | 8,955,000Source | 8,135,000Source | 9,181,000Source | 10,548,000Source |
| Operating Lease, Right-of-Use AssetUSD | 376,000Source | 628,000Source | 1,346,000Source | 438,000Source | 692,000Source | 1,445,000Source | 501,000Source | 757,000Source | 1,544,000Source | 565,000Source | 824,000Source | 715,000Source |
| Other Assets, NoncurrentUSD | 1,299,000Source | 951,000Source | 4,550,000Source | 931,000Source | 961,000Source | 4,285,000Source | 910,000Source | 960,000Source | 2,175,000Source | 951,000Source | 1,129,000Source | 384,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 21,297,000Source | 20,778,000Source | 31,807,000Source | 19,358,000Source | 28,204,000Source | 30,775,000Source | 12,474,000Source | 27,200,000Source | 32,021,000Source | 23,332,000Source | 48,932,000Source | 18,508,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 10,000Source | 156,000Source | 17,000Source | 8,000Source | 10,000Source | 14,000Source | 7,000Source | 74,000Source | 13,000Source | 4,000Source | 59,000Source | 76,000Source |
| Retained Earnings (Accumulated Deficit)USD | -807,805,000Source | -708,586,000Source | -935,461,000Source | -775,795,000Source | -694,373,000Source | -894,909,000Source | -747,523,000Source | -615,597,000Source | -854,715,000Source | -730,694,000Source | -600,658,000Source | -470,038,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -274,000Source | -250,000Source | -348,000Source | -270,000Source | -243,000Source | -283,000Source | -266,000Source | -240,000Source | -289,000Source | -255,000Source | -232,000Source | -167,000Source |
| Stockholders' Equity Attributable to ParentUSD | 231,143,000Source | 74,211,000Source | 222,281,000Source | 168,001,000Source | 42,103,000Source | 227,137,000Source | 180,396,000Source | 108,143,000Source | 245,150,000Source | 139,558,000Source | 105,525,000Source | 207,182,000Source |
| Additional Paid in Capital, Common StockUSD | 1,039,212,000Source | 782,891,000Source | 1,158,073,000Source | 944,058,000Source | 736,709,000Source | 1,122,315,000Source | 928,178,000Source | 723,906,000Source | 1,100,141,000Source | 870,503,000Source | 706,356,000Source | 677,311,000Source |
| Liabilities and EquityUSD | 252,440,000Source | 94,989,000Source | 254,088,000Source | 187,359,000Source | 70,307,000Source | 257,912,000Source | 192,870,000Source | 135,343,000Source | 277,171,000Source | 162,890,000Source | 154,457,000Source | 225,690,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 21,031,000Source | 15,181,000Source | 30,785,000Source | 19,061,000Source | 22,043,000Source | 29,647,000Source | 12,146,000Source | 20,479,000Source | 30,837,000Source | 18,307,000Source | 18,884,000Source | 18,180,000Source |
| Operating Lease, Liability, CurrentUSD | 159,000Source | 275,000Source | 250,000Source | 195,000Source | 277,000Source | 162,000Source | 235,000Source | 277,000Source | 125,000Source | 274,000Source | 270,000Source | 432,000Source |
| Accounts Payable, CurrentUSD | 8,540,000Source | 3,935,000Source | 9,051,000Source | 7,783,000Source | 10,406,000Source | 9,649,000Source | 4,193,000Source | 6,649,000Source | 8,114,000Source | 4,546,000Source | 3,782,000Source | 8,068,000Source |
| Operating Lease, Liability, NoncurrentUSD | 266,000Source | 425,000Source | 1,022,000Source | 297,000Source | 493,000Source | 1,128,000Source | 328,000Source | 563,000Source | 1,184,000Source | 358,000Source | 632,000Source | 328,000Source |
| Additional Financial Items | ||||||||||||
| Long-term Debt, Excluding Current Maturities | — | —Source | — | — | —Source | — | — | —Source | — | —Source | —Source | — |
| Long-term Debt, Current MaturitiesUSD | — | 2,820,000Source | — | — | 2,820,000Source | — | — | 2,820,000Source | — | 2,820,000Source | 2,350,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | — | 5,172,000Source | — | — | 5,668,000Source | — | — | 6,158,000Source | — | 4,667,000Source | 6,561,000Source | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 555,000Source | 493,000Source | 1,925,000Source | 3,421,000Source | 4,291,000Source | 1,253,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,970,000Source | 882,000Source | 6,017,000Source | 4,778,000Source | 9,275,000Source | 10,914,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 2,548,000Source | -371,000Source | 2,619,000Source | 3,683,000Source | — | — |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -2,369,000Source | -272,000Source | -1,726,000Source | -3,741,000Source | -61,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -42,318,000Source | -16,579,000Source | -99,844,000Source | -60,925,000Source | -102,003,000Source | -98,053,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -1,692,000Source | -6,000Source | -4,528,000Source | -120,000Source | -29,070,000Source | -48,147,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 1,692,000Source | 6,000Source | 3,369,000Source | 120,000Source | 7,895,000Source | 48,147,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | 2,902,000Source | — | 3,047,000Source | 13,760,000Source | — | 13,965,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 20,205,000Source | 49,533,000Source | 214,530,000Source | 134,872,000Source | 36,517,000Source | 87,844,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | 9,650,000Source | 9,650,000Source | 2,350,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -23,799,000Source | 32,939,000Source | 110,127,000Source | 73,831,000Source | -94,621,000Source | -58,430,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 191,349,000Source | 29,136,000Source | 176,619,000Source | 126,236,000Source | 186,008,000Source | 132,619,000Source | 209,807,000Source | 99,680,000Source | 25,849,000Source | 120,470,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | 117,000Source | 89,000Source | 1,234,000Source | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 6,000Source | -9,000Source | -31,000Source | 4,000Source | -65,000Source | -74,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | — | 1,837,000Source | — | — | — |
| Amortization of Intangible AssetsUSD | — | — | 0Source | 0Source | — | — | 0Source | 0Source | 0Source | 476,000Source | 477,000Source | — |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | — | — | — | — | — | — | 6,150,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | — | — | — | — | 62,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | 0Source | 0Source | — | — | 0Source | -2,092,000Source | -2,092,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 30,215,000Source |
| GoodwillUSD | — | — | — | — | — | — | — | — | — | — | 965,000Source | — |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | 965,000Source | — | — |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | — | 9,200,000Source | — | — |
| InterestExpenseNonoperatingUSD | — | — | — | 301,000Source | — | — | — | — | 89,000Source | — | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | 669,000Source | 1,490,000Source | — | — |
| Investment Income, InterestUSD | — | — | 1,231,000Source | 18,000Source | — | — | 1,346,000Source | 394,000Source | 4,146,000Source | — | 1,722,000Source | 1,873,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -32,010,000Source | -14,213,000Source | -40,552,000Source | -28,272,000Source | -40,194,000Source | -16,829,000Source | -124,021,000Source | -130,036,000Source | -116,658,000Source | -110,218,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -32,010,000Source | -14,213,000Source | -40,552,000Source | -28,272,000Source | -40,194,000Source | -16,829,000Source | -124,021,000Source | -130,036,000Source | -116,658,000Source | -116,877,000Source |
| Operating Lease, ExpenseUSD | — | — | 100,000Source | 100,000Source | 100,000Source | 100,000Source | 100,000Source | 100,000Source | 300,000Source | 300,000Source | 600,000Source | 600,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -1,156,000Source | -44,000Source | -49,000Source | -1,955,000Source | -3,000Source | 394,000Source | -3,295,000Source | -2,079,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 20,126,000Source | 62,230,000Source | 237,940,000Source | 140,195,000Source | 18,939,000Source | 94,463,000Source |
| Financing Receivable, Credit Loss, Expense (Reversal)USD | — | — | — | — | — | — | — | — | 31,000Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 3,290,000Source | 2,822,000Source | 13,544,000Source | 1,998,000Source | 6,878,000Source | 2,429,000Source | 13,107,000Source | 10,094,000Source | 7,768,000Source | — |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | — |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 25,701,000Source | 7,707,000Source | 35,959,000Source | 16,202,000Source | 28,624,000Source | 10,104,000Source | 87,684,000Source | 40,101,000Source | 34,752,000Source | — |
| Operating Income (Loss)USD | — | — | -33,067,000Source | -15,554,000Source | -42,535,000Source | -28,296,000Source | -41,537,000Source | -16,054,000Source | -125,703,000Source | -136,701,000Source | -118,380,000Source | -112,091,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -1,156,000Source | -44,000Source | -49,000Source | -1,955,000Source | -3,000Source | 394,000Source | -3,295,000Source | -2,079,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -32,010,000Source | -14,213,000Source | -40,552,000Source | -28,272,000Source | -40,194,000Source | -16,829,000Source | -124,021,000Source | -130,036,000Source | -116,658,000Source | -110,218,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -3.59Source | -22.68Source | -2.44Source | -3.86Source | -2.93Source | -2.84Source | -14.57Source | -176.6Source | -6.85Source | -3.27Source |
| Earnings Per Share, DilutedUSD per share | — | — | -3.59Source | -22.68Source | -2.44Source | -3.86Source | -2.93Source | -2.84Source | -14.57Source | -176.6Source | -6.85Source | -3.27Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 8,922,792Source | 626,669Source | 16,635,254Source | 7,327,257Source | 13,707,104Source | 5,927,231Source | 8,511,318Source | 736,339Source | 17,039,309Source | 35,739,057Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 8,922,792Source | 626,669Source | 16,635,254Source | 7,327,257Source | 13,707,104Source | 5,927,231Source | 8,511,318Source | 736,339Source | 17,039,309Source | 35,739,057Source |
| Interest Expense (non-operating)USD | — | — | — | 301,000Source | — | — | — | — | 89,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 0Source | 0Source | — | — | 0Source | 0Source | 0Source | 476,000Source | 477,000Source | — |
| Costs and ExpensesUSD | — | — | 36,357,000Source | 18,376,000Source | 56,079,000Source | 30,294,000Source | 48,415,000Source | 18,483,000Source | 138,810,000Source | 146,795,000Source | 126,148,000Source | 112,091,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 400,000Source | 500,000Source | 600,000Source | 500,000Source | 600,000Source | 500,000Source | 1,900,000Source | 2,900,000Source | 3,800,000Source | 1,253,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | — | — | — | — | — | — | 6,150,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 30,215,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | 965,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -34,033,000Source | -80,592,000Source | -18,454,000Source | -21,740,000Source |
| Investment Income, InterestUSD | — | — | 1,231,000Source | 18,000Source | — | — | 1,346,000Source | 394,000Source | 4,146,000Source | — | 1,722,000Source | 1,873,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -32,010,000Source | -14,213,000Source | -40,552,000Source | -28,272,000Source | -40,194,000Source | -16,829,000Source | -124,021,000Source | -130,036,000Source | -116,658,000Source | -116,877,000Source |
| Operating Lease, ExpenseUSD | — | — | 100,000Source | 100,000Source | 100,000Source | 100,000Source | 100,000Source | 100,000Source | 300,000Source | 300,000Source | 600,000Source | 600,000Source |
| Preferred Stock Dividends and Other AdjustmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 6,659,000Source |
| Research and Development ExpenseUSD | — | — | 9,289,000Source | 9,114,000Source | 19,417,000Source | 10,820,000Source | 18,213,000Source | 7,436,000Source | 44,486,000Source | 39,972,000Source | 86,655,000Source | 81,876,000Source |
| Interest Income (Expense), Nonoperating, Net | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Marketing and Advertising Expense | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Filing attachments
ex107.htm · S-8 · 2026-07-01
Calculation of Filing Fee Tables S-8 Tonix Pharmaceuticals Holding Corp. ─────────────────────────────────────── Table 1: Newly Registered Securities ──────────────────────────────────────── Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee ───────────────────────────…
Read attachment ↗ex4-02.htm · 10-K · 2026-03-12
Tonix Pharmaceuticals Holding Corp. 10-K Exhibit 4.02 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a summary of all material characteristics of our common stock as set forth in our articles of incorporation and bylaws. The summary does not purport to be complete and is qualified in its entirety by reference to our articles of incorporation and bylaws, each as amended, and to the provisions of Chapter 78 of…
Read attachment ↗ex4-01.htm · 8-K · 2025-12-29
EX-4.01 3 ex4-01.htm FORM OF PRE-FUNDED WARRANT TONIX PHARMACEUTICALS HOLDING CORP. 8-K EXHIBIT 4.01 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK TONIX PHARMACEUTICALS HOLDING CORP. Warrant Shares: Original Issuance Date: December 30, 2025 ────────────────────────────────────────────────────────────────── THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, [•] or its assigns (the “Holder”) is entitled, upon th…
Read attachment ↗ex99-1.htm · 8-K · 2025-10-22
EX-99.1 2 ex99-1.htm PRESS RELEASE TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.01 Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix’s investigational intranasal potentiated oxytocin products in patients with Arginine-Vasopressin Deficiency (AVP-D) Th…
Read attachment ↗ex99-1.htm · 8-K · 2025-07-10
EX-99.1 2 ex99-1.htm PRESS RELEASE TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.1 Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025 TNX-801 is up to 100,000-fold less virulent than live smallpox vaccine strains and a single dose provides robust immunogenicity and protection against mpox and rabbitpox (more than one year) in animals Subcutaneous administration of TNX-801 yielded equivalent protection …
Read attachment ↗ex99-2.htm · 8-K · 2025-07-10
EX-99.2 3 ex99-2.htm COMPANY PRESENTATION TONIX PHARMACEUTICALS HOLDING CORP. 8-K Exhibit 99.2 TNX - 801, A SINGLE - DOSE LIVE VACCINE PLATFORM FOR MPOX AND OTHER EMERGING VIRAL DISEASES: SAFETY, IMMUNOGENICITY, AND EFFICACY Sina Bavari, Ph. D. World Congress on Vaccines July 10 th, 2025 © 2025 Tonix Pharmaceuticals Holding Corp. 2 © 2025 Tonix Pharmaceuticals Holding Corp. DISCLAIMER "Certain statements in this presentation regarding strategic plans, expectations and objectives for futur…
Read attachment ↗